Table 2.

Selected clinical studies of novel agents in AL amyloidosis

Selected clinical studies of novel agents in AL amyloidosis

BIW, twice weekly bortezomib schedule; Bortez, bortezomib; CR, complete response rate; Cytox, cyclophosphamide; dex, dexamethasone; Len, lenalidomide; mel or M, melphalan; new, untreated patients; NR, not reported; Pom, pomalidomide; QW, weekly bortezomib schedule; RR, response rate; SCT, autologous stem cell transplant; series, retrospective series; Thal, thalidomide

Close Modal

or Create an Account

Close Modal
Close Modal